journal article·2023-01Open access

Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6

Clément Bechtler, Sophia Koutsogiannaki, Ekaterina Umnyakova, Amal Hamid, Avneesh Gautam, Yiannis Sarigiannis, Richard B. Pouw, Christina Lamers, Said Rabbani, Christoph Q. Schmidt, John D. Lambris, Daniel Ricklin

Acta Biomaterialia· Volume 155

Abstract

The use of biomaterials in modern medicine has enabled advanced drug delivery strategies and led to reduced morbidity and mortality in a variety of interventions such as transplantation or hemodialysis. However, immune-mediated reactions still present a serious complication of these applications. One of the drivers of such reactions is the complement system, a central part of humoral innate immunity that acts as a first-in-line defense system in its own right but also coordinates other host defense responses. A major regulator of the complement system is the abundant plasma protein factor H (FH), which impairs the amplification of complement responses. Previously, we could show that it is possible to recruit FH to biomedical surfaces using the phage display-derived cyclic peptide 5C6 and, consequently, reduce deposition of C3b, an activation product of the complement system. However, the optimal orientation of 5C6 on surfaces, structural determinants within the peptide for the binding, and the exact binding region on FH remained unknown. Here, we show that the cyclic core and C-terminal region of 5C6 are essential for its interaction with FH and that coating through its N-terminus strongly increases FH recruitment and reduces C3-mediated opsonization in a microparticle-based assay. Furthermore, we could demonstrate that 5C6 selectively binds to FH but not to related proteins. The observation that 5C6 also binds murine FH raises the potential for translational evaluation in animal models. This work provides important insight for the future development of 5C6 as a probe or therapeutic entity to reduce complement activation on biomaterials. STATEMENT OF SIGNIFICANCE: Biomaterials have evolved into core technologies critical to biomedical and drug delivery applications alike, yet their safe and efficient use may be adversely impacted by immune responses to the foreign materials. Taking inspiration from microbial immune evasion strategies, our group developed a peptide-based surface coating that recruits factor H (FH), a host regulator of the complement system, from plasma to the material surface and prevents unwanted activation of this innate immunity pathway. In this study, we identified the molecular determinants that define the interaction between FH and the coated peptide, developed tethering strategies with largely enhanced binding capacity and provided important insight into the target selectivity and species specificity of the FH-binding peptide, thereby paving the way for preclinical development steps.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Complement system in diseases · Peptidase Inhibition and Analysis · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Understanding interactions between biomaterials and biological systems using proteomics10.1016/j.biomaterials.2018.03.020 ↗
2. Complement inhibition in biomaterial- and biosurface-induced thromboinflammation10.1016/j.smim.2016.04.006 ↗
3. Therapeutic modulation of the complement system in kidney transplantation: clinical indications and emerging drug leads10.3389/fimmu.2019.02306 ↗
4. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts10.1681/ASN.2014040399 ↗
5. Update on C1 esterase inhibitor in human solid organ transplantation10.1097/TP.0000000000002717 ↗
6. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis10.1182/blood-2010-01-264051 ↗
7. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles10.1038/s41565-018-0344-3 ↗
8. Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines10.1021/acsnano.0c03648 ↗
9. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?10.1016/j.it.2009.09.005 ↗
10. Complement in disease: a defence system turning offensive10.1038/nrneph.2016.70 ↗
11. S.C. Skinner, V.K. Derebail, C.J. Poulton, D.C. Bunch, P. Roy-Chaudhury, N.S. Key, Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review., Kidney Med. 3 (n.d.) 607–618. https://doi.org/10.1016/j.xkme.2021.04.006.10.1016/j.xkme.2021.04.006 ↗
12. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement10.1016/j.jconrel.2021.11.042 ↗
13. Complement opsonization of nanoparticles: Differences between humans and preclinical species10.1016/j.jconrel.2021.08.048 ↗
14. The multifaceted role of complement in kidney transplantation10.1038/s41581-018-0071-x ↗
15. Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides10.1016/j.biomaterials.2009.01.001 ↗
16. Self-damage caused by dysregulation of the complement alternative pathway: relevance of the factor H protein family10.3389/fimmu.2018.01607 ↗
17. Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling10.1006/jmbi.2001.4720 ↗
18. The central portion of factor H (Modules 10-15) is compact and contains a structurally deviant CCP module10.1016/j.jmb.2009.10.010 ↗
19. Solution structure of CCP modules 10–12 illuminates functional architecture of the complement regulator, factor H10.1016/j.jmb.2012.09.013 ↗
20. Protection of host cells by complement regulators10.1111/imr.12475 ↗
21. Complement evasion by human pathogens10.1038/nrmicro1824 ↗
22. A receptor for the complement regulator factor H increases transmission of trypanosomes to tsetse flies10.1038/s41467-020-15125-y ↗
23. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine10.4049/jimmunol.1003802 ↗
24. A new map of glycosaminoglycan and C3b binding sites on factor H10.4049/jimmunol.181.4.2610 ↗
25. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating10.1016/j.biomaterials.2012.10.040 ↗
26. Complement factor H related proteins (CFHRs)10.1016/j.molimm.2013.06.001 ↗
27. Production of biologically active complement factor H in therapeutically useful quantities10.1016/j.pep.2010.12.002 ↗
28. Protein-binding assays in biological liquids using microscale thermophoresis10.1038/ncomms1093 ↗
29. Macrocyclization strategies for cyclic peptides and peptidomimetics10.1039/D1MD00083G ↗
30. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet10.1016/j.ab.2008.03.035 ↗
31. Functional characterization of alternative and classical pathway C3/C5 convertase activity and inhibition using purified models10.3389/fimmu.2018.01691 ↗
32. C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases10.1073/pnas.2102787118 ↗
33. Biological applications of magnetic nanoparticles10.1039/c2cs15337h ↗
34. Complement factor H-related protein 3 serum levels are low compared to factor h and mainly determined by gene copy number variation in CFHR310.1371/journal.pone.0152164 ↗
35. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera10.1182/bloodadvances.2018025692 ↗
36. Of mice and men: The factor H protein family and complement regulation10.1016/j.molimm.2015.03.011 ↗
37. The EMBL-EBI search and sequence analysis tools APIs in 201910.1093/nar/gkz268 ↗
38. UniProt: the universal protein knowledgebase in 202110.1093/nar/gkaa1100 ↗
39. Clinical promise of next-generation complement therapeutics10.1038/s41573-019-0031-6 ↗
40. Tipping the balance: intricate roles of the complement system in disease and therapy
41. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties10.1016/j.imbio.2012.06.003 ↗
42. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters10.1016/j.imbio.2014.10.026 ↗
43. Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood10.1111/xen.12262 ↗
44. From discovery to approval: a brief history of the compstatin family of complement C3 inhibitors
45. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: Surface-bound factor H inhibits complement activation10.1016/S0142-9612(00)00431-2 ↗
46. Surface-attached PEO in the form of activated pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model10.1002/jbm.a.30377 ↗
47. Therapeutic lessons to be learned from the role of complement regulators as double-edged sword in health and disease10.3389/fimmu.2020.578069 ↗
48. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties10.4049/jimmunol.1203548 ↗
49. Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy10.1038/s41551-017-0187-5 ↗
50. Macrocyclization strategies for cyclic peptides and peptidomimetics10.1039/D1MD00083G ↗
51. PEGylation, successful approach to drug delivery10.1016/S1359-6446(05)03575-0 ↗
52. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process10.1016/j.molimm.2008.08.276 ↗
53. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation10.1016/j.jconrel.2016.06.040 ↗
54. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration10.1016/j.exer.2021.108583 ↗
55. Electrostatic interactions contribute to the folded-back conformation of wild type human factor H10.1016/j.jmb.2009.06.010 ↗
56. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation10.4049/jimmunol.179.7.4451 ↗
57. New concepts of complement in allorecognition and graft rejection10.1016/j.cellimm.2007.04.009 ↗
58. Antibody-mediated rejection: emergence of animal models to answer clinical questions10.1111/j.1600-6143.2010.03065.x ↗
59. In vivo evaluation of the biocompatibility of biomaterial device10.1007/978-981-15-3262-7_8 ↗